Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.72
+0.07000.25%
Post-market: 27.730.0123+0.04%19:59 EDT
Volume:25.56M
Turnover:705.42M
Market Cap:157.61B
PE:36.48
High:27.85
Open:27.80
Low:27.42
Close:27.65
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.91
T/O Rate:0.45%
Dividend:1.72
Dividend Rate:6.21%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.85
PE(LYR):20.32

Loading ...

Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 14

Moderately bullish activity in Pfizer with shares up 1.1%

TIPRANKS
·
Jul 14

Pfizer is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 13

BMO Capital Adjusts Price Target on Pfizer to $30 From $34, Maintains Outperform Rating

MT Newswires Live
·
Jul 13

Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug

MT Newswires Live
·
Jul 13

Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen

Simply Wall St.
·
Jul 12

Pfizer (PFE) Juggles Fresh Trial Wins Amid Analyst Doubt

TIPRANKS
·
Jul 11

Developer Behind the Buckling NYC High Rise is Being Sued over Another Conversion

Dow Jones
·
Jul 11

Why Verizon, Clorox and More Dividend Stocks are Flashing a Buy Signal

Dow Jones
·
Jul 11

Pfizer is Maintained at Neutral by B of a Securities

Dow Jones
·
Jul 11

Sector Update: Healthcare

MT Newswires Live
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

TIPRANKS
·
Jul 10

FDA Approves Pfizer Padcev-keytruda Combo for Perioperative Muscle-invasive Bladder Cancer

Reuters
·
Jul 10

U.S. FDA Approves Padcev® Plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-invasive Bladder Cancer Regardless of Cisplatin Eligibility

THOMSON REUTERS
·
Jul 10

FDA: Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Jul 10

BofA Securities Adjusts Pfizer Price Target to $26 From $27

MT Newswires Live
·
Jul 10

Pfizer Seen Reporting Q2 Revenue In Line With Consensus, EPS Below Estimates, RBC Says

MT Newswires Live
·
Jul 10

Market Chatter: Pfizer's Vaccine Disputes With Poland, Romania Continue

MT Newswires Live
·
Jul 10

Pfizer price target lowered to $26 from $27 at BofA

TIPRANKS
·
Jul 10